Sisram Medical (HKG:1696) said its sublicensed-in botulinum toxin type A for injection passed the quality testing from China's National Institutes for Food and Drug Control, according to a Monday Hong Kong bourse filing.
The product is indicated for a temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscles activity in adult patients.